Free Trial

Aquestive Therapeutics Q3 2023 Earnings Report

Aquestive Therapeutics logo
$2.71 -0.16 (-5.57%)
As of 04/4/2025 04:00 PM Eastern

Aquestive Therapeutics EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Aquestive Therapeutics Revenue Results

Actual Revenue
$13.00 million
Expected Revenue
$11.33 million
Beat/Miss
Beat by +$1.67 million
YoY Revenue Growth
N/A

Aquestive Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Remove Ads

Aquestive Therapeutics Earnings Headlines

Aquestive Therapeutics' (AQST) Buy Rating Reaffirmed at HC Wainwright
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Aquestive Therapeutics (AQST) Gets a Buy from Lake Street
Aquestive announces positive results from pediatric study for Anaphylm
See More Aquestive Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aquestive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aquestive Therapeutics and other key companies, straight to your email.

About Aquestive Therapeutics

Aquestive Therapeutics (NASDAQ:AQST) operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

View Aquestive Therapeutics Profile

More Earnings Resources from MarketBeat